Dynamic Technology Lab Private Ltd Takes Position in Valeant Pharmaceuticals International, Inc. (VRX)

Dynamic Technology Lab Private Ltd acquired a new position in Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 16,267 shares of the specialty pharmaceutical company’s stock, valued at approximately $179,000.

Several other institutional investors have also modified their holdings of the company. Paulson & CO. Inc. acquired a new position in shares of Valeant Pharmaceuticals International during the fourth quarter worth approximately $281,463,000. Norges Bank acquired a new position in shares of Valeant Pharmaceuticals International during the fourth quarter worth approximately $39,286,000. Renaissance Technologies LLC boosted its position in shares of Valeant Pharmaceuticals International by 573.6% in the fourth quarter. Renaissance Technologies LLC now owns 2,913,089 shares of the specialty pharmaceutical company’s stock worth $42,294,000 after buying an additional 2,480,600 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new position in shares of Valeant Pharmaceuticals International during the fourth quarter worth approximately $8,495,000. Finally, Two Sigma Investments LP acquired a new position in shares of Valeant Pharmaceuticals International during the fourth quarter worth approximately $7,823,000. 50.45% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) traded down 1.56% during midday trading on Tuesday, hitting $13.26. 3,196,055 shares of the stock traded hands. The company’s 50-day moving average is $12.38 and its 200 day moving average is $12.92. Valeant Pharmaceuticals International, Inc. has a 12-month low of $8.31 and a 12-month high of $32.74. The firm’s market cap is $4.61 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $1.93. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. The business had revenue of $2.11 billion during the quarter, compared to analyst estimates of $2.17 billion. During the same quarter last year, the firm posted ($1.08) earnings per share. The business’s revenue for the quarter was down 11.1% compared to the same quarter last year. On average, analysts anticipate that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Dynamic Technology Lab Private Ltd Takes Position in Valeant Pharmaceuticals International, Inc. (VRX)” was originally reported by sleekmoney and is owned by of sleekmoney. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://sleekmoney.com/dynamic-technology-lab-private-ltd-takes-position-in-valeant-pharmaceuticals-international-inc-vrx/1924379.html.

A number of equities analysts have commented on VRX shares. Royal Bank Of Canada reissued a “sector perform” rating and issued a $18.00 price objective (down from $21.00) on shares of Valeant Pharmaceuticals International in a research note on Thursday, March 23rd. Stifel Nicolaus reissued a “buy” rating and issued a $35.00 price objective (down from $45.00) on shares of Valeant Pharmaceuticals International in a research note on Wednesday, May 17th. Deutsche Bank AG dropped their price objective on shares of Valeant Pharmaceuticals International from $19.00 to $18.00 and set a “hold” rating for the company in a research note on Wednesday, April 19th. Piper Jaffray Companies reissued an “outperform” rating and issued a $10.00 price objective on shares of Valeant Pharmaceuticals International in a research note on Friday, April 14th. Finally, Scotiabank lifted their price objective on shares of Valeant Pharmaceuticals International from $12.00 to $14.00 and gave the stock a “sector perform” rating in a research note on Wednesday, May 10th. Three research analysts have rated the stock with a sell rating, fourteen have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $16.26.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 20,000 shares of the stock in a transaction dated Thursday, May 11th. The stock was acquired at an average price of $13.90 per share, with a total value of $278,000.00. Following the completion of the purchase, the director now owns 70,572 shares in the company, valued at approximately $980,950.80. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 5.87% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Want to see what other hedge funds are holding VRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX).

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/dynamic-technology-lab-private-ltd-takes-position-in-valeant-pharmaceuticals-international-inc-vrx/1924379.html

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *